摘要
目的探讨131I治疗甲亢早期动态变化,评价其治疗效果。方法对303例接受131I治疗的甲亢患者,在治疗后6个月分别进行了随访,了解其症状、体征及用放射免疫法和免疫放射分析法测定的血清甲状腺激素浓度,并对结果进行统计学处理。结果治疗前和治疗后6个月症状、体征明显改善,各激素值较治疗时均有明显变化,且差别都有显著的统计学意义(P<0.05),新增6例突眼患者。303例患者中,249例(82.2%)痊愈,21例(6.9%)好转,24例(7.9%)出现甲低,9例(3.0%)无效。总有效率为97.3%,治愈率为90.1%。结论131I治疗甲亢经济、简便、安全、有效,可作为Graves病的首选治疗方法。
Objective To explore the inchoate changes in patients with Graves disease （GD） treated with ^131I and appraise the therapeutic effect. Methods According to the thyroid size, patients＇ age, thyroid ^131I intake rate and course of the disease, 303 patients with GD were given individual ^131I doses. Six months later, the symptom, signs, and thyroid hormone levels of every case were compared with those recorded before. Results The symptom and the level of thyroid hormones were significantly meliorated after ^131I treatment. Six cases became goggle-eyed after treatment. Among the 303 patients, 249（82.18% ） fully recovered, 21 （6. 93% ） partially remitted, 24（7.92% ） developed hypothyroidism, and 9（2.97% ） showed ineffective. Conclusion ^131I treatment for GD with an individual dose can exert a satisfied therapeutic efficacy. It may as serve the first choice for GD treatment.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2007年第7期635-637,共3页
Journal of Third Military Medical University
